Accelerated DNA methylation age and the use of antihypertensive medication among older adults

Xu Gao*, Elena Colicino, Jincheng Shen, Allan C. Just, Jamaji C. Nwanaji-Enwerem, Brent Coull, Xihong Lin, Pantel Vokonas, Yinan Zheng, Lifang Hou, Joel Schwartz, Andrea A. Baccarelli

*Corresponding author for this work

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The discrepancy of DNA methylation age (DNAmAge) with chronological age (termed as age acceleration, AA) has been identified to be associated with many aging-related health outcomes including hypertension. Since taking antihypertensive medication (AHM) could prevent aging-related diseases caused by hypertension, we hypothesized that using AHM could also reduce the AA. We examined this hypothesis among 546 males aged 55-85 years by exploring the associations of AHM use with AA and its change rate (ΔAA) in two visits with a median follow-up of 3.86 years. Horvath DNAmAge was derived from DNA methylation profiles measured by Illumina HumanMethylation450 BeadChip and information on AHM use was collected by physician interview. A general decreasing pattern of AA was observed between the two visits. After the fully adjusting for potential covariates including hypertension, any AHM use showed a cross-sectional significant association with higher AA at each visit, as well as a longitudinal association with increased ΔAA between visits. Particularly, relative to participants who never took any AHM, individuals with continuous AHM use had a higher ΔAA of 0.6 year/chronological year. This finding underlines that DNAmAge and AA may not be able to capture the preventive effects of AHMs that reduce cardiovascular risks and mortality.

Original languageEnglish (US)
Pages (from-to)3210-3228
Number of pages19
JournalAging
Volume10
Issue number11
DOIs
StatePublished - Nov 1 2018

Fingerprint

DNA Methylation
Antihypertensive Agents
Hypertension
Interviews
Physicians
Mortality
Health

Keywords

  • Aging
  • Antihypertensive medication
  • DNA methylation age
  • Epigenetic epidemiology
  • Hypertension

ASJC Scopus subject areas

  • Aging
  • Cell Biology

Cite this

Gao, X., Colicino, E., Shen, J., Just, A. C., Nwanaji-Enwerem, J. C., Coull, B., ... Baccarelli, A. A. (2018). Accelerated DNA methylation age and the use of antihypertensive medication among older adults. Aging, 10(11), 3210-3228. https://doi.org/10.18632/aging.101626
Gao, Xu ; Colicino, Elena ; Shen, Jincheng ; Just, Allan C. ; Nwanaji-Enwerem, Jamaji C. ; Coull, Brent ; Lin, Xihong ; Vokonas, Pantel ; Zheng, Yinan ; Hou, Lifang ; Schwartz, Joel ; Baccarelli, Andrea A. / Accelerated DNA methylation age and the use of antihypertensive medication among older adults. In: Aging. 2018 ; Vol. 10, No. 11. pp. 3210-3228.
@article{3fc7fcd2e1b742ffac094f432c7b96cc,
title = "Accelerated DNA methylation age and the use of antihypertensive medication among older adults",
abstract = "The discrepancy of DNA methylation age (DNAmAge) with chronological age (termed as age acceleration, AA) has been identified to be associated with many aging-related health outcomes including hypertension. Since taking antihypertensive medication (AHM) could prevent aging-related diseases caused by hypertension, we hypothesized that using AHM could also reduce the AA. We examined this hypothesis among 546 males aged 55-85 years by exploring the associations of AHM use with AA and its change rate (ΔAA) in two visits with a median follow-up of 3.86 years. Horvath DNAmAge was derived from DNA methylation profiles measured by Illumina HumanMethylation450 BeadChip and information on AHM use was collected by physician interview. A general decreasing pattern of AA was observed between the two visits. After the fully adjusting for potential covariates including hypertension, any AHM use showed a cross-sectional significant association with higher AA at each visit, as well as a longitudinal association with increased ΔAA between visits. Particularly, relative to participants who never took any AHM, individuals with continuous AHM use had a higher ΔAA of 0.6 year/chronological year. This finding underlines that DNAmAge and AA may not be able to capture the preventive effects of AHMs that reduce cardiovascular risks and mortality.",
keywords = "Aging, Antihypertensive medication, DNA methylation age, Epigenetic epidemiology, Hypertension",
author = "Xu Gao and Elena Colicino and Jincheng Shen and Just, {Allan C.} and Nwanaji-Enwerem, {Jamaji C.} and Brent Coull and Xihong Lin and Pantel Vokonas and Yinan Zheng and Lifang Hou and Joel Schwartz and Baccarelli, {Andrea A.}",
year = "2018",
month = "11",
day = "1",
doi = "10.18632/aging.101626",
language = "English (US)",
volume = "10",
pages = "3210--3228",
journal = "Aging",
issn = "1945-4589",
publisher = "US Administration on Aging",
number = "11",

}

Gao, X, Colicino, E, Shen, J, Just, AC, Nwanaji-Enwerem, JC, Coull, B, Lin, X, Vokonas, P, Zheng, Y, Hou, L, Schwartz, J & Baccarelli, AA 2018, 'Accelerated DNA methylation age and the use of antihypertensive medication among older adults', Aging, vol. 10, no. 11, pp. 3210-3228. https://doi.org/10.18632/aging.101626

Accelerated DNA methylation age and the use of antihypertensive medication among older adults. / Gao, Xu; Colicino, Elena; Shen, Jincheng; Just, Allan C.; Nwanaji-Enwerem, Jamaji C.; Coull, Brent; Lin, Xihong; Vokonas, Pantel; Zheng, Yinan; Hou, Lifang; Schwartz, Joel; Baccarelli, Andrea A.

In: Aging, Vol. 10, No. 11, 01.11.2018, p. 3210-3228.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Accelerated DNA methylation age and the use of antihypertensive medication among older adults

AU - Gao, Xu

AU - Colicino, Elena

AU - Shen, Jincheng

AU - Just, Allan C.

AU - Nwanaji-Enwerem, Jamaji C.

AU - Coull, Brent

AU - Lin, Xihong

AU - Vokonas, Pantel

AU - Zheng, Yinan

AU - Hou, Lifang

AU - Schwartz, Joel

AU - Baccarelli, Andrea A.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - The discrepancy of DNA methylation age (DNAmAge) with chronological age (termed as age acceleration, AA) has been identified to be associated with many aging-related health outcomes including hypertension. Since taking antihypertensive medication (AHM) could prevent aging-related diseases caused by hypertension, we hypothesized that using AHM could also reduce the AA. We examined this hypothesis among 546 males aged 55-85 years by exploring the associations of AHM use with AA and its change rate (ΔAA) in two visits with a median follow-up of 3.86 years. Horvath DNAmAge was derived from DNA methylation profiles measured by Illumina HumanMethylation450 BeadChip and information on AHM use was collected by physician interview. A general decreasing pattern of AA was observed between the two visits. After the fully adjusting for potential covariates including hypertension, any AHM use showed a cross-sectional significant association with higher AA at each visit, as well as a longitudinal association with increased ΔAA between visits. Particularly, relative to participants who never took any AHM, individuals with continuous AHM use had a higher ΔAA of 0.6 year/chronological year. This finding underlines that DNAmAge and AA may not be able to capture the preventive effects of AHMs that reduce cardiovascular risks and mortality.

AB - The discrepancy of DNA methylation age (DNAmAge) with chronological age (termed as age acceleration, AA) has been identified to be associated with many aging-related health outcomes including hypertension. Since taking antihypertensive medication (AHM) could prevent aging-related diseases caused by hypertension, we hypothesized that using AHM could also reduce the AA. We examined this hypothesis among 546 males aged 55-85 years by exploring the associations of AHM use with AA and its change rate (ΔAA) in two visits with a median follow-up of 3.86 years. Horvath DNAmAge was derived from DNA methylation profiles measured by Illumina HumanMethylation450 BeadChip and information on AHM use was collected by physician interview. A general decreasing pattern of AA was observed between the two visits. After the fully adjusting for potential covariates including hypertension, any AHM use showed a cross-sectional significant association with higher AA at each visit, as well as a longitudinal association with increased ΔAA between visits. Particularly, relative to participants who never took any AHM, individuals with continuous AHM use had a higher ΔAA of 0.6 year/chronological year. This finding underlines that DNAmAge and AA may not be able to capture the preventive effects of AHMs that reduce cardiovascular risks and mortality.

KW - Aging

KW - Antihypertensive medication

KW - DNA methylation age

KW - Epigenetic epidemiology

KW - Hypertension

UR - http://www.scopus.com/inward/record.url?scp=85058105134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058105134&partnerID=8YFLogxK

U2 - 10.18632/aging.101626

DO - 10.18632/aging.101626

M3 - Article

C2 - 30414594

AN - SCOPUS:85058105134

VL - 10

SP - 3210

EP - 3228

JO - Aging

JF - Aging

SN - 1945-4589

IS - 11

ER -

Gao X, Colicino E, Shen J, Just AC, Nwanaji-Enwerem JC, Coull B et al. Accelerated DNA methylation age and the use of antihypertensive medication among older adults. Aging. 2018 Nov 1;10(11):3210-3228. https://doi.org/10.18632/aging.101626